Scholarlink

<p>Bispecific antibodies (BsAbs), which simultaneously target two antigens and redirect immune T cells toward tumor cells, have emerged as one of the most promising immunotherapeutic strategies for multiple myeloma (MM). Based on previously reported clinical data, several BsAbs have been approved for MM patients who relapsed in late-line treatment. At the 2025 ASH Annual Meeting, pivotal trials presented updated findings on BsAbs targeting B-cell maturation antigen (BCMA), G-protein-coupled receptor family C group 5 member D (GPRC5D), and Fc receptor-homolog 5 (FcRH5), evaluated as monotherapies or in combination regimens across patient populations, both at initial diagnosis and at relapse. Here, we summarize the remarkable outcomes from the key clinical trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Breakthroughs of bispecific antibodies therapy in multiple myeloma: latest updates from 2025 ASH

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月10日

查看全文
  • Bihuan Zhao,
  • Qiling Bu,
  • Ai-Li Chen,
  • Hong-Hu Zhu

摘要

Bispecific antibodies (BsAbs), which simultaneously target two antigens and redirect immune T cells toward tumor cells, have emerged as one of the most promising immunotherapeutic strategies for multiple myeloma (MM). Based on previously reported clinical data, several BsAbs have been approved for MM patients who relapsed in late-line treatment. At the 2025 ASH Annual Meeting, pivotal trials presented updated findings on BsAbs targeting B-cell maturation antigen (BCMA), G-protein-coupled receptor family C group 5 member D (GPRC5D), and Fc receptor-homolog 5 (FcRH5), evaluated as monotherapies or in combination regimens across patient populations, both at initial diagnosis and at relapse. Here, we summarize the remarkable outcomes from the key clinical trials.